The continuum of care for ALK-positive NSCLC: from diagnosis to new treatment options - an overview.

The role of the ALK receptor in cancer biology B. Hallberg & R. H. Palmer iii4 Precision medicine in NSCLC and pathology: how does ALK fit in the pathway? K. M. Kerr & F. López-Ríos iii16 ALK evaluation in the world of multiplex testing: Network Genomic Medicine (NGM): the Cologne model for implementing personalised oncology C. Heydt, A. Kostenko, S. Merkelbach-Bruse, J. Wolf & R. Büttner iii25 Crizotinib: from discovery to accelerated development to front-line treatment F. Blackhall & F. Cappuzzo iii35 Crizotinib resistance: implications for therapeutic strategies I. Dagogo-Jack & A. T. Shaw iii42

[1]  A. Shaw,et al.  Crizotinib resistance: implications for therapeutic strategies. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  J. Wolf,et al.  ALK evaluation in the world of multiplex testing: Network Genomic Medicine (NGM): the Cologne model for implementing personalised oncology. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  R. Palmer,et al.  The role of the ALK receptor in cancer biology. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  F. Blackhall,et al.  Crizotinib: from discovery to accelerated development to front-line treatment. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  K. Kerr,et al.  Precision medicine in NSCLC and pathology: how does ALK fit in the pathway? , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  F. Cappuzzo,et al.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.

[7]  William Pao,et al.  Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. , 2014, JAMA.

[8]  G. Giaccone,et al.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. , 2013, The Journal of molecular diagnostics : JMD.

[9]  Michael Thomas,et al.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.

[10]  Jeffrey W. Clark,et al.  Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. , 2012, The Lancet. Oncology.

[11]  J. Soria,et al.  Tumour molecular profiling for deciding therapy—the French initiative , 2012, Nature Reviews Clinical Oncology.

[12]  Jeffrey W. Clark,et al.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.

[13]  Marc Ladanyi,et al.  Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. , 2010, The New England journal of medicine.

[14]  S. Ogawa,et al.  Oncogenic mutations of ALK kinase in neuroblastoma , 2008, Nature.

[15]  John M. Maris,et al.  Identification of ALK as a major familial neuroblastoma predisposition gene , 2008, Nature.

[16]  Laura A. Sullivan,et al.  Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer , 2007, Cell.

[17]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[18]  D N Shapiro,et al.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.